Alzheimer Disease Detection using AI with Deep Learning based Features with Development and Validation based on Data Science

Abstract

Alzheimer's disease (AD), a neurological condition that worsens over time, affects millions of individuals worldwide. Because of this, effective intervention and therapy depend on early and precise detection. In recent years, encouraging findings have been obtained using data science and artificial intelligence (AI) techniques in the field of medical diagnostics, particularly AD diagnosis. This work seeks to develop an accurate algorithm for diagnosing AD by identifying AI-based traits from neuroimaging and clinical data.The three key steps of the proposed methodology are data preprocessing, feature extraction, and model development and validation. To offer neuroimaging data, such as MRI and PET scans, as well as essential clinical information, a cohort of persons made up of AD patients and healthy controls is obtained. Throughout the preparation stage, the data are normalised, standardised, and quality-checked to ensure accuracy and consistency.The critical role of feature extraction in locating critical patterns and features potentially indicative of AD is critical. Advanced AI techniques like Convolutional Neural Networks and Recurrent Neural Networks are utilised to extract discriminative features from neuroimaging data after subjecting it to feature engineering methods.The retrieved features are then utilised to build a prediction model using state-of-the-art machine learning techniques such as Support Vector Machines (SVM), Random Forests, or Deep Learning architectures. Strict validation methods, such cross-validation and test datasets, are used to evaluate the model's performance in order to ensure generalizability and minimise overfitting.The project's objective is to identify AD with high specificity, sensitivity, and accuracy to support early diagnosis and tailored treatment planning. The results of this research contribute to the body of knowledge on AI-based diagnostics for neurodegenerative diseases and have the potential to significantly impact clinical practises by facilitating early interventions and improving patient outcomes. It is important to take into account the size and heterogeneity of the dataset as well as any prospective improvements and future expansions to the usage of AI in AD detection.